Advanced Filters
noise

Liver Cancer Clinical Trials

A listing of Liver Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 630 clinical trials
S Sanna Norén, MD, PhDstudent

Hemostasis in Liver Cirrhosis and Hepatocellular Cancer

Evaluating hemostasis in decompensated liver cirrhosis with novel hemostatic assays.

18 years of age All Phase N/A
M Michael Pavlides, DPhil

Abbreviated Magnetic Resonance Imaging vs Ultrasound Surveillance for Liver Cancer dETection in People at High Risk of Developing Liver Cancer

Aim: To use magnetic resonance imaging (MRI) scans without contrast to help improve diagnosis of liver cancer in people who are at increased risk of developing liver cancer. Background: People with any condition that affects the liver over a long period of time can develop cirrhosis. Conditions and risk factors …

18 years of age All Phase N/A
L Ledu Zhou, PhD

Antiviral Therapy for Patients With Liver Cancer After Surgery

This is a single-center, prospective, observational, real world study designed to evaluate the effects of peginterferon α-2b(pegabin) combined with nucleoside (acid) analogs (entecavir,ETV tenofovir,TDF tenofovir alafenamide,TAF) on patients after radical surgery for hepatitis B associated hepatocellular carcinoma by collecting data from patients at our hospital

18 - 65 years of age All Phase N/A

The Optimal Number of Fiducial Marker for Stereotactic Body Radiotherapy

This is a clinical study focused on the use of fiducial marker-guided stereotactic body radiotherapy (SBRT) for treating malignant tumors, including lung, liver, pancreatic, and kidney/adrenal cancers. Here's a breakdown of the key components of the study: Study Design: Prospective, single-center, exploratory clinical study. Patient Enrollment: The study intends to …

18 years of age All Phase N/A

Analysis of PD-L1, TMB, MSI and ctDNA Dynamics to Predict and Monitor Response to Immunotherapy in Metastatic Cancer.

This is an observational clinical trial, aiming to investigate whether the ctDNA dynamics could predict early response to ICIs in patients with advanced-stage cancer. Moreover, conventional tumor markers PD-L1, TMB and MSI are to be investigated for their combined prognostic values in ICI treatment.

18 - 80 years of age All Phase N/A

Advanced Therapies for Liver Metastases

Liver metastases (MTS) are the main cause of death for patients affected by colorectal carcinoma (CRC) and pancreatic ductal adenocarcinoma (PDAC), thus representing the major unmet clinical need for these malignancies. Based on preliminary and published data, the investigators hypothesize that innovative immune, gene and cell therapy approaches might overcome …

18 years of age All Phase N/A
W Weilin Wang

Early-stage Detection of Liver Cancer by Proteins in Peripheral Blood

By collecting blood samples from liver cancer patients and healthy individuals, and comparing the blood protein profiles of the two, the biomarkers for early diagnosis and tissue traceability were identified to accurately establish an early diagnosis model for liver cancer and verify its efficacy.

18 - 75 years of age All Phase N/A
E Eleanor Barnes, Prof

The Detection of Small Early Liver Cancer With Natural History Follow up

The SELINA study will recruit 200 patients with cirrhosis and small HCC and 50 patients with HCC but without cirrhosis (most of whom are expected to have FLD). Blood, urine and liver tissue samples (where available) will be collected for laboratory analysis. In a subgroup of patients (N=80, around 64 …

18 - 100 years of age All Phase N/A
J Jing Liang

A Retrospective Study on the Treatment of Intermediate and Advanced Liver Cancer.

To evaluate the effectiveness of TACE combined with immunotherapy and targeted therapy versus TACE alone in patients with intermediate and advanced liver cancer.

18 years of age All Phase N/A
J Jinbo Yue, doctor

Radiotherapy Delays Second-line Drug Therapy for Oligo Progressive Primary Liver Cancer

Recent years have seen significant advancements in the treatment landscape of advanced hepatocellular carcinoma (HCC), with the emergence of targeted and immunotherapy strategies reshaping first-line therapy. Sorafenib, a multi-targeted tyrosine kinase inhibitor, initially set the standard, followed by approvals for lenvatinib, regorafenib, cabozantinib, and ramucirumab. Immunotherapy, particularly combinations like atezolizumab …

18 - 75 years of age All Phase N/A

Simplify language using AI